title: Galectin-2 suppresses contact allergy by inducing apoptosis in activated CD8+ T cells.
abstract: Galectins, a family of structurally related beta-galactoside-binding proteins, are expressed by various cells of the immune systems and seem to be important for the regulation of immune responses and immune cell homeostasis. Since it has been demonstrated that galectin-2 regulates cell-mediated inflammatory bowel disease and colitis in mice, we intended to investigate the role of galectin-2 in inflammatory cutaneous T cell-mediated immune responses. To address this issue, groups of naive mice were sensitized to the contact allergen 2,4-dinitro-1-fluorobenzene and systemically treated with galectin-2 to analyze the effects of galectin-2 on contact allergy. Here we show that galectin-2 is expressed in murine skin and is up-regulated upon cutaneous inflammation. Interestingly, treatment of mice with galectin-2 significantly reduced the contact allergy response. This effect was long-lasting since rechallenge of galectin-2-treated mice after a 14-day interval still resulted in a decreased ear swelling. We were able to demonstrate that galectin-2 induced a reduction of MHC class I-restricted immune responses in the treated animals, which was mediated by the induction of apoptosis specifically in activated CD8(+) T cells. Additionally, we report that the galectin-2-binding protein CD29 is up-regulated on the surface of activated CD8(+) T cells compared with naive CD8(+) T cells or CD4(+) T cells, suggesting that increased galectin-2/CD29 signaling might be responsible for the proapoptotic effects of galectin-2 on activated CD8(+) T cells. Taken together, these data indicate that galectin-2 may represent a novel therapeutic alternative for the treatment of CD8-mediated inflammatory disorders such as contact allergy.
authors.affiliation: Department of Dermatology, University of Münster, Münster, Germany. loserk@uni-muenster.de
authors.forename: Karin
authors.initials: K
authors.lastname: Loser
authors.forename: Andreas
authors.initials: A
authors.lastname: Sturm
authors.forename: Maik
authors.initials: M
authors.lastname: Voskort
authors.forename: Verena
authors.initials: V
authors.lastname: Kupas
authors.forename: Sandra
authors.initials: S
authors.lastname: Balkow
authors.forename: Matteo
authors.initials: M
authors.lastname: Auriemma
authors.forename: Carlo
authors.initials: C
authors.lastname: Sternemann
authors.forename: Axel U
authors.initials: AU
authors.lastname: Dignass
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Luger
authors.forename: Stefan
authors.initials: S
authors.lastname: Beissert
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000473:pathology; D002478:Cells, Cultured; D003877:Dermatitis, Contact / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D037501:Galectin 2 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000037:antagonists & inhibitors / Q000378:metabolism; D018836:Inflammation Mediators / Q000378:metabolism; D008213:Lymphocyte Activation / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics / Q000627:therapeutic use; D012867:Skin / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D015854:Up-Regulation / Q000276:immunology
chemical_list: D037501:Galectin 2; D007166:Immunosuppressive Agents; D018836:Inflammation Mediators; C511926:LGALS2 protein, human; D011994:Recombinant Proteins